Global Brain Tumor Drugs Market (2022 to 2031) - Featuring Pfizer, Shimadzu and Celgene Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Brain Tumor Drugs Global Market Report 2022, Type, Drugs, End User" report has been added to ResearchAndMarkets.com's offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the global brain tumor drugs market as it emerges from the COVID-19 shut down.
The global brain tumor drugs market is expected to grow from $3.17 billion in 2021 to $3.49 billion in 2022 at a compound annual growth rate (CAGR) of 10.2%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.84 billion in 2026 at a CAGR of 8.5%.
- Pfizer Inc.
- Shimadzu Corporation
- Toshiba Medical Systems
- Merck & Co. Inc.
- Carestream Health
- Philips Healthcare
- Siemens Healthineers
- Hitachi Medical Corporation
- GE Healthcare
- Novartis AG
- Bristol-Myers Squibb
- Astellas Pharma
- Johnson & Johnson
- Genetech U.S.A
- Hoffmann- La Roche
- Antisense Pharma
- Macleods Pharmaceutical Limited
- Mankind Pharma
- Dr. Reddys Laboratories Ltd.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain. These drugs are either used alone or in combinations, depending on the type, size and locations of the tumor.
The main types of drugs in brain tumor drugs are temozolomide, carmustine, cisplatin, bevacizumab, geftinib and erlotinib. Temozolomide is a drug that is intended to treat some types of brain cancer (e.g., glioblastoma multiforme, anaplastic astrocytoma) in individuals who have had tumours return or who have recently been diagnosed with tumours. It's one of a class of drugs called as antineoplastics (cancer medicines). The different types include medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal (PNET), others (glioma, acoustic neuroma, meningioma) and is used in various sectors such as hospital pharmacies, clinics and others.
North America is the largest region in the brain tumor drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The major driving factor responsible for the growth of Brain Tumor market is the increasing prevalence of Neurological Disorders, worldwide. Neurological Disorders are identified as one of the most prevalent disorders, due to longer life expectancy, increasing exposure to infections and sedentary lifestyle. For example, as per the National Brain Tumor Society, around 700,000 people in the United States around 700,00 people are having primary brain tumor in 2019 and around 86,000more will be diagnosed. The increasing number of patients with neurological disorders including brain tumor, is leading to a rise in the demand for the drugs used in their treatment.
Increasing use of targeted therapies is acting as a restraint on the Brain Tumor drugs market. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of targeted cancer therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. For example, Everolimus is a targeted therapy that specially blocks the cancer cells from growing and spreading. Similarly, Bevacizumab prevents regeneration of cancer cells unlike chemical drugs which cannot prevent regeneration. This rising popularity of targeted therapies is expected to affect the sales of conventional chemical Brain Tumor drugs, thus restraining the growth of the market during the forecast period.
For more information about this report visit https://www.researchandmarkets.com/r/5m22xy
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900